CLU and Parkinson disease: In this regard, it would be important to understand if genetic deletion or down‐regulation of clusterin levels in vivo would improve the clearance of aggregated α‐synuclein by astrocytes, protect neurons from the spreading of toxic forms of α‐synuclein and thus be neuroprotective for PD.